Novo’s own head-to-head could not show CagriSema was as good as tirzepatide. I take Zepbound myself, and I go through both sets of numbers, plus the brand names Novo has filed, including Wegovamy.
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on reta, from VYNRETA to YEZRETA. Here is the whole list, which domains Lilly quietly bought first, and what happened the last time it did this.
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I take Zepbound, I lost about 170 pounds on it, and I am staying put.
My coronary calcium score is zero. What a zero doesn’t rule out, what a new NEJM study found about plaque without calcium, and whether the $2,000 AI heart scan (Cleerly or HeartFlow) is worth it at 53.
I do not take a statin. I got my ApoB to 59 with about 170 pounds of weight loss and a generic ezetimibe that runs me twenty dollars a month, so when a big statin trial reads out I have nothing invested in the answer. I have also written here about why most of the
Updated September 16, 2026 with the revised label now posted to DailyMed. The FDA approved Mounjaro today to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high risk for those events. That is a real expansion, and for a lot of people it is
Not one of them tested an injury. I pulled every record in FDA’s July 2026 review and the registries behind it.
An ApoB of 60 mg/dL sits at about the 10th percentile of untreated American adults, lower than roughly nine of every ten, under even the goal the 2026 guideline reserves for its high-risk patients, and inside the range the longevity crowd treats as the destination. By every framework I can find, a 60 is a
An ApoB of 90 mg/dL is the most average result an American adult can get. ApoB is in effect a particle count: every particle that can push cholesterol into an artery wall carries exactly one copy of it. In the National Lipid Association’s percentile table for untreated US adults, 90 is the 50th percentile. Whether
My first ApoB result was 95 mg/dL, in May 2025. Labcorp flagged it high, because Labcorp’s reference range tops out at 90. Cleveland Clinic publishes a normal range for men of 66 to 133, so the same tube of blood at a different lab would have come back with no flag at all. Whether my
